Methods for direct detection of individual methotrexate metabolites
AssigneePrometheus Laboratories Inc.
InventorsThierry Dervieux, Russell B. Richerson
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for determining a level of a methotrexate polyglutamate (MTXPG) in a cellular extract by resolving at least one MTXPG in a cellular extract obtained from a human undergoing methotrexate therapy; and detecting at least one resolved MTXPG, thereby determining a level of the resolved MTXPG. A method of the invention can be useful, for example, for determining a level of MTXPG3, MTXPG4 or MTXPG5 or for determining a level of each methotrexate polyglutamate species (MTXPG1 to MTXPG7) present in the cellular extract.
Claims85
A method for determining a level of a methotrexate polyglutamate (MTXPG) in a cellular extract, comprising:
- (a) resolving at least one MTXPG in a cellular extract obtained from a human undergoing methotrexate therapy;
- and
- (b) detecting at least one resolved MTXPG, thereby determining a level of said resolved MTXPG.
A method for determining a level of a methotrexate polyglutamate (MTXPG) in a cellular extract, comprising:
- (a) resolving at least one MTXPG in the cellular extract, wherein said MTXPG contains no more than a natural abundance of radioactive isotopes;
- and
- (b) detecting at least one resolved MTXPG, thereby determining a level of said resolved MTXPG,
- wherein detection of said resolved MTXPG does not require fractionation of said resolved MTXPG from other MTXPG species.
A method for determining a level of a methotrexate polyglutamate (MTXPG) in a cellular extract, comprising:
- (a) resolving at least one MTXPG in the cellular extract;
- (b) irradiating said at least one MTXPG, thereby producing at least one resolved fluorescent MTXPG photolytic product;
- and
- (c) detecting said at least one resolved fluorescent MTXPG photolytic product, thereby determining a level of said MTXPG.
A method of optimizing therapeutic efficacy or reducing toxicity associated with methotrexate (MTX) therapy administered to a human, comprising:
- (a) resolving at least one MTXPG in a cellular extract obtained from said human;
- (b) detecting at least one resolved MTXPG, thereby determining a level of said resolved MTXPG;
- and
- (c) selecting a drug or dosage to be subsequently administered to said human based on said level of resolved MTXPG.
Dependencies are inferred from the claim text.